NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
February 09, 2023 04:01 ET
|
NRG Therapeutics Limited
Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UKJoins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at...
Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives
January 04, 2023 16:15 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
November 17, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
November 15, 2022 08:00 ET
|
Vyant Bio, Inc.
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered...
Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
September 07, 2022 07:00 ET
|
Attralus, Inc
AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosisAT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer's ...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
August 11, 2022 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease
October 19, 2020 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors
September 09, 2020 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
June 08, 2020 08:15 ET
|
Cognition Therapeutics, Inc.
New York, June 08, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting
October 15, 2019 08:03 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...